Using a lactacystin-induced model of PD, Ba, et al. [33] found that 4 weeks of lf-rTMS administration reduced the levels of the pro-apoptotic enzyme caspace-3 and inflammatory markers tumor necrosis factor-α (TNFα), and cyclooxygenase-2 (COX-2). This evidence concerns the gene PTGS2 and Parkinson disease.